Companies Orchestra BioMed Holdings
Orchestra BioMed (OBIO): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Orchestra BioMed Holdings’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $6,911,218FY2023
- $1,912,475FY2024
- $2,261,233FY2025
CEO total pay was $2,261,233 in fiscal 2025, up from $1,912,475 in fiscal 2024.
FY2025: salary $595,000 · bonus $0 · stock awards $791,399 · option awards $290,575
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| David Hochman | $595,000 | $0 | $791,399 | $290,575 | $572,009 | $0 | $12,250 | $2,261,233 |
| Chief Executive Officer & Chairman | ||||||||
| Darren Sherman | 495,000 | 0 | 631,354 | 84,840 | 475,873 | 0 | 70,767 | 1,757,835 |
| President & Chief Operating Officer | ||||||||
| Andrew Taylor | 409,583 | 0 | 439,840 | 0 | 297,778 | 0 | 59,316 | 1,206,517 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| David Hochman | $2,261,233 | $1,912,475 | $6,911,218 | ↑ +348,758 |
| Darren Sherman | 1,757,835 | 1,794,277 | 6,459,297 | ↓ −36,442 |
| Andrew Taylor | 1,206,517 | 1,060,409 | 2,398,749 | ↑ +146,108 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The executive compensation program is designed to attract, retain and reward key employees, to incentivize them based on the achievement of key performance goals, and to align their interests with the interests of our stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | FW Cook |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Andrew Taylor | RSU | — | — | — | 80,000 | — | — |
| Andrew Taylor | RSU | 2023-07-20 | — | — | 278,363 | — | — |
Vehicle mix — grant-date fair value by award type
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Darren Sherman | Option | 42,000 | 2.85 | — |
| Andrew Taylor | RSU | 63,749 | — | 264,558 |
| David Hochman | RSU | 70,000 | — | 290,500 |
| David Hochman | Option | 72,659 | 7.42 | — |
| Andrew Taylor | RSU | 80,000 | — | 332,000 |
| Andrew Taylor | RSU | 83,720 | — | 347,438 |
| Andrew Taylor | RSU | 84,000 | — | 348,600 |
| Darren Sherman | RSU | 84,667 | — | 351,368 |
| David Hochman | RSU | 98,333 | — | 408,082 |
| Darren Sherman | RSU | 112,625 | — | 467,394 |
| Darren Sherman | RSU | 115,708 | — | 480,188 |
| Darren Sherman | RSU | 120,000 | — | 498,000 |
| David Hochman | RSU | 127,498 | — | 529,117 |
| David Hochman | Option | 147,500 | 2.76 | — |
| David Hochman | RSU | 200,000 | — | 830,000 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Chris ClearyIndependent · Audit | $50,417 | $135,664 | $205,417 | — | $0 | $391,498 |
| Eric S. Fain, M.DIndependent · Lead Independent Director · Compensation (Chair) · Nominating and Corporate Governance | 95,000 | 78,999 | 85,001 | — | 0 | 259,000 |
| Pamela Y. ConnealyIndependent · Nominating and Corporate Governance · Audit | 70,000 | 78,999 | 85,001 | — | 0 | 234,000 |
| David PacittiIndependent · Compensation · Audit | 62,500 | 78,999 | 85,001 | — | 0 | 226,500 |
| Jason M. AryehIndependent · Compensation · Nominating and Corporate Governance (Chair) | 62,500 | 78,999 | 85,001 | — | 0 | 226,500 |
| John MackIndependent · Audit | 55,000 | 78,999 | 85,001 | — | 0 | 219,000 |
| Darren R. ShermanEmployee director | — | — | — | — | — | 0 |
| David P. HochmanEmployee director · Board Chair | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $125,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $395,417 |
| Equity awards (grant-date value) | $530,659 |
| All other compensation | $0 |
| Total cost of the board | $926,076 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Orchestra BioMed as a peer
Companies that benchmark against OBIO
1 company names OBIO as a compensation peer
The list of companies that name OBIO as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | AxoGen | 2025 | Michael Dale | $775,865 | $7,342,895 | $0 | $906,133 | $9,047,454 |
| 2 | Pulse Biosciences | 2025 | Paul LaViolette | 708,523 | 0 | 6,717,960 | 0 | 7,427,899 |
| 3 | EyePoint Pharmaceuticals | 2025 | Jay Duker | 696,251 | 1,610,700 | 2,604,113 | 632,700 | 5,568,352 |
| 4 | Humacyte | 2025 | Laura Niklason | 633,606 | 0 | 4,332,725 | 0 | 5,234,908 |
| 5 | CVRx | 2025 | Kevin Hykes | 660,533 | 1,270,080 | 1,516,896 | 444,492 | 3,905,801 |
| 6 | LeMaitre Vascular | 2025 | George LeMaitre | 806,347 | 1,050,000 | 1,050,000 | 680,015 | 3,780,990 |
| 7 | Tactile Systems Tech | 2025 | Sheri Dodd | 675,000 | 2,019,978 | 0 | 737,438 | 3,466,916 |
| 8 | Senseonics Holdings | 2025 | Timothy Goodnow | 635,000 | 1,022,500 | 1,022,500 | 613,000 | 3,347,959 |
| 9 | Orchestra BioMed Holdings | 2025 | David Hochman | 595,000 | 791,399 | 290,575 | 572,009 | 2,261,233 |
| 10 | Elutia | 2025 | C. Randal Mills | 600,000 | — | — | 738,000 | 1,344,284 |
| 11 | Hyperfine | 2025 | Maria Sainz | 582,231 | 0 | 0 | 314,586 | 896,817 |
| 12 | Stereotaxis | 2025 | David Fischel | 60,000 | — | — | — | 64,390 |
| — | Zynex | — | — | — | — | — | — | not in coverage universe |
| — | Ligand Pharmaceuticals | — | — | — | — | — | — | not in coverage universe |
| — | Pulmonx | — | — | — | — | — | — | not in coverage universe |
| — | PAVmed | — | — | — | — | — | — | not in coverage universe |
| — | Lyra Therapeutics | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Orchestra BioMed Holdings | not disclosed | not disclosed | not disclosed | FW Cook |
| AxoGen | 116.79% | PSU 50 · RSU 50 | No | Aon |
| CVRx | Kevin Hykes: 84%; Robert John: 66%; Philip Adamson: 84%% | Stock Options 50 · RSUs 50 | not disclosed | Aon |
| Elutia | not disclosed | not disclosed | not disclosed | not disclosed |
| EyePoint Pharmaceuticals | not disclosed | not disclosed | not disclosed | Aon |
| Humacyte | 80% | not disclosed | not disclosed | Aon plc |
| Hyperfine | not disclosed | not disclosed | not disclosed | Compensia |
| LeMaitre Vascular | not disclosed | Option 50 · RSU 25 · PSU 25 | No | not disclosed |
| Ligand Pharmaceuticals | not disclosed | not disclosed | not disclosed | not disclosed |
| Lyra Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| PAVmed | not disclosed | not disclosed | not disclosed | not disclosed |
| Pulmonx | not disclosed | not disclosed | not disclosed | not disclosed |
| Pulse Biosciences | not disclosed | not disclosed | not disclosed | not disclosed |
| Senseonics Holdings | not disclosed | not disclosed | not disclosed | Willis Towers Watson |
| Stereotaxis | not disclosed | not disclosed | not disclosed | not disclosed |
| Tactile Systems Tech | 115% | PSU 50 · RSU 50 | No | Aon Consulting, Inc. |
| Zynex | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-23 | 37,975,986 | 1,778,200 | 67,523 | 95.37% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-23 | 95.37%a |
a. Approved under the standard stated in the filing — “4 : Approval of the Say-on-Pay Proposal requires the affirmative vote of the holders of a majority of the shares of our common stock present in person, by remote communication, or represented by proxy at the Annual Meeting and entitled to vote thereon to be approved. || Abstentions: Stockholder abstentions are considered shares present and entitled to vote on this proposal, and thus, will have the same effect as a vote "Against" this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (28 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, David Hochman. DEF 14A, filed 2026-04-29. Section “Executive Compensation” · page 34. As printed: 2,261,233. View filing ↗
- Section 01, Darren Sherman. DEF 14A, filed 2026-04-29. Section “Executive Compensation”. As printed: 1,757,835. View filing ↗
- Section 01, Andrew Taylor. DEF 14A, filed 2026-04-29. Section “Executive Compensation”. As printed: 1,206,517. View filing ↗
- Section 03, Andrew Taylor RSU. DEF 14A, filed 2026-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Taylor RSU. DEF 14A, filed 2026-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Chris Cleary. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 391,498. View filing ↗
- Section 08, Eric S. Fain, M.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 259,000. View filing ↗
- Section 08, Pamela Y. Connealy. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 234,000. View filing ↗
- Section 08, David Pacitti. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 226,500. View filing ↗
- Section 08, Jason M. Aryeh. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 226,500. View filing ↗
- Section 08, John Mack. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 219,000. View filing ↗
- Section 08, Darren R. Sherman. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, David P. Hochman. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-23. Item 5.07 · say-on-pay result. As reported: 95.37% (votes for as printed: 37,975,986). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 395,417 + equity 530,659 + all other 0 = 926,076, summed across the director compensation table rows.
- AxoGen, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in AxoGen's own proxy. As printed: 9,047,454. View filing ↗
- Pulse Biosciences, Section 10b CEO total. DEF 14A, filed 2026-05-11. CEO total compensation as printed in Pulse Biosciences's own proxy. As printed: 7,427,899. View filing ↗
- EyePoint Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in EyePoint Pharmaceuticals's own proxy. As printed: 5,568,352. View filing ↗
- Humacyte, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Humacyte's own proxy. As printed: 5,234,908. View filing ↗
- CVRx, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in CVRx's own proxy. As printed: 3,905,801. View filing ↗
- LeMaitre Vascular, Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in LeMaitre Vascular's own proxy. As printed: 3,780,990. View filing ↗
- Tactile Systems Tech, Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Tactile Systems Tech's own proxy. As printed: 3,466,916. View filing ↗
- Senseonics Holdings, Section 10b CEO total. DEFR 14A, filed 2026-04-09. CEO total compensation as printed in Senseonics Holdings's own proxy. As printed: 3,347,959. View filing ↗
- Orchestra BioMed Holdings (subject), Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Orchestra BioMed Holdings's own proxy. As printed: 2,261,233. View filing ↗
- Elutia, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Elutia's own proxy. As printed: 1,344,284. View filing ↗
- Hyperfine, Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Hyperfine's own proxy. As printed: 896,817. View filing ↗
- Stereotaxis, Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Stereotaxis's own proxy. As printed: 64,390. View filing ↗